Form 4: iSpecimen Inc. Director Andrew L. Ross Reports Stock Option Grant

Director Andrew L. Ross reports the acquisition of stock options in iSpecimen Inc.

Summary

• On January 2, 2024, Andrew L. Ross, a director of iSpecimen Inc. (ISPC), was granted stock options for 10,000 shares.
• The exercise price of these options is $0.53 per share.
• The options vest in four equal installments of 2,500 shares each on March 31, 2024, June 30, 2024, September 30, 2024, and December 31, 2024.
• Following this transaction, Ross directly owns 33,525 derivative securities.
• The options expire on January 1, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common practice for incentivizing and retaining key personnel, including directors, in publicly traded companies. This aligns the director's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and healthcare sectors, similar to companies like Bio-Rad Laboratories and Thermo Fisher Scientific.
• The vesting schedule of quarterly installments is also a common practice to incentivize continued service and performance.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.

Key Dates

Keywords

iSpecimen Inc., ISPC, stock options, Form 4, director, Andrew L. Ross, beneficial ownership, equity securities